Imatinib Sandoz (Imatinib)

Imatinib Sandoz targets specific tyrosine‑kinase driven cancers and is indicated for the following conditions:

• Chronic myeloid leukemia (CML): reduces malignant cell proliferation and achieves durable molecular responses.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves remission rates when combined with chemotherapy.
• Gastrointestinal stromal tumour (GIST): inhibits tumor growth driven by KIT or PDGFRA mutations.

• Imatinib selectively inhibits the BCR‑ABL fusion protein as well as the c‑KIT and PDGFR tyrosine kinases. By binding to the ATP‑binding pocket of these enzymes, it blocks downstream signaling pathways that drive uncontrolled cell division, thereby inducing apoptosis and slowing tumour progression.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent tightening of skeletal muscles.
• Fatigue: generalized tiredness.
• Diarrhoea: loose stools, usually self‑limited.
• Rash: mild skin erythema.

Serious or Rare Side Effects

• Severe neutropenia: marked reduction in white blood cells.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Cardiac failure: reduced heart function, especially in patients with pre‑existing disease.
• Pulmonary hypertension: increased pressure in lung arteries.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Tumour lysis syndrome: rapid tumour cell breakdown causing metabolic disturbances.

Patients should be monitored closely for safety concerns before and during therapy.

• Blood count monitoring: perform complete blood counts regularly to detect cytopenias.
• Liver function assessment: check hepatic enzymes prior to initiation and periodically thereafter.
• Cardiac evaluation: assess baseline cardiac status and monitor for signs of heart failure.
• Hypersensitivity awareness: discontinue if severe allergic reactions occur.
• Pregnancy considerations: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib plasma levels.
• Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): can markedly reduce drug exposure.
• Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 substrates (e.g., midazolam, tacrolimus): may require dose adjustments.
• QT‑prolonging agents (e.g., quinidine, sotalol): monitor cardiac rhythm.
• Vaccines (live attenuated): consider timing to avoid reduced vaccine efficacy.